2025
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial
Borlaug B, Testani J, Petrie M, Wang Z, Cunningham J, Adams K, Amir O, Bělohlávek J, Bocchi E, Freitas A, Hominal M, Kadokami T, Merkely B, Miller C, Nuñez J, Verma S, Yilmaz M, Oru E, Sam F. Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial. Nature Medicine 2025, 1-9. PMID: 40887551, DOI: 10.1038/s41591-025-03939-6.Peer-Reviewed Original ResearchEstimated glomerular filtration rateLA reservoir strainLong-acting formHeart failureReservoir strainNT-proBNPKidney functionHuman relaxinRenal serious adverse eventsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptidePhase 2 randomized trialNT-proBNP levelsPreserved Ejection FractionSerious adverse eventsGlomerular filtration rateDouble-blindEjection fractionSecondary endpointsMulticenter trialNatriuretic peptideDecompensated HFpEFLA functionHF hospitalizationAdverse eventsDapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
Berg D, Patel S, Haller P, Cange A, Palazzolo M, Bellavia A, Kuder J, Desai A, Inzucchi S, McMurray J, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi M, Drasnar T, Izzo J, Sarman B, McGinty J, Ramanathan K, Mulkay A, Przybylski A, Ruff C, O'Donoghue M, Murphy S, Sabatine M, Wiviott S. Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure. Circulation 2025 PMID: 40884036, DOI: 10.1161/circulationaha.125.076575.Peer-Reviewed Original ResearchSodium-glucose cotransporter-2 inhibitorsRisk of cardiovascular deathIn-hospital initiationInitiation of sodium-glucose cotransporter-2 inhibitorsCotransporter-2 inhibitorsInitiation of dapagliflozinHeart failureHospitalized HF patientsPlacebo groupCardiovascular deathSymptomatic hypotensionHF patientsKidney functionMeta-analysisEarly riskMeta-analysis of patientsPlacebo-controlled trialRandomized clinical trial dataAll-cause deathAll-Cause MortalityRandomized clinical trialsClinical trial dataDapagliflozin groupDouble-blindEfficacy outcomesMachine learning-based prediction of tubulointerstitial lesions in diabetic kidney disease: a multicenter validation study
Xu C, Shen Z, Zhong Y, Han S, Liao H, Duan Y, Tian X, Ren X, Lu C, Jiang H. Machine learning-based prediction of tubulointerstitial lesions in diabetic kidney disease: a multicenter validation study. Renal Failure 2025, 47: 2547266. PMID: 40841991, PMCID: PMC12372483, DOI: 10.1080/0886022x.2025.2547266.Peer-Reviewed Original ResearchConceptsDiabetic kidney diseaseDecision curve analysisTubulointerstitial lesionsKidney diseaseIdentification of high-risk patientsEarly identification of high-risk patientsManagement of diabetic kidney diseaseDeterioration of renal functionProgression of diabetic kidney diseaseHigh-risk patientsEarly identificationExternal validation cohortMulticenter validation studyBiopsy puncturesRenal functionClinical benefitMulticenter studyValidation cohortInvasive biopsyPrecision nephrologyMetabolic markersKidney functionInternal validityMultivariate analysisPathological featuresUrine Proteomic Signatures of Kidney Function Decline after Hospitalization
Wen Y, Menez S, Philbrook H, Moledina D, Coca S, Xue J, Kaufman J, Chinchillil V, Kimmel P, Ikizler T, Hsu C, Kelly T, Ricardo A, Himmelfarb J, Parikh C. Urine Proteomic Signatures of Kidney Function Decline after Hospitalization. JCI Insight 2025, 10 PMID: 40794429, DOI: 10.1172/jci.insight.195577.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUrine proteomic signatureKidney Precision Medicine ProjectEGFR declineHistopathological featuresTubular injuryUrinary proteinFeatures of acute kidney injuryHigh riskAssociated with eGFR declineSlower eGFR declineAssociated with eGFRGlomerular filtration rateKidney function declineResearch kidney biopsiesYear Follow-UpKidney biopsyInterstitial inflammationMyeloid cellsKidney injuryProximal tubulesFiltration rateFollow-upKidney functionIndependent cohortDevelopment of a prediction tool for kidney function decline in children with chronic kidney disease
Moon S, Noh J, Kang H, Lee K, Shin J, Song J, Baek H, Cho M, Jung J, Lee J, Cho H, Han K, Yang E, Kim S, Kim J, Park E, Ahn Y. Development of a prediction tool for kidney function decline in children with chronic kidney disease. Kidney Research And Clinical Practice 2025 PMID: 40905038, DOI: 10.23876/j.krcp.25.004.Peer-Reviewed Original ResearchEstimated glomerular filtration rateKidney function declineChronic kidney diseasePediatric patientsProgression to kidney replacement therapyBaseline estimated glomerular filtration rateKidney diseaseFunctional declinePediatric chronic kidney diseasePediatric CKD cohortsGlomerular filtration rateProtein-to-creatinine ratioUrine protein-to-creatinine ratioDecline of kidney functionPotential predictorsKidney replacement therapyReplacement therapyHemoglobin levelsCKD cohortFiltration rateKidney functionLaboratory dataPatientsKidneyTreatment useAutosomal dominant polycystic kidney disease without apparent family history: A single-center experience.
Samuels M, Maarouf O, Zeng W, Hamrahian M, Dahl N, Zhang J. Autosomal dominant polycystic kidney disease without apparent family history: A single-center experience. Clinical Nephrology 2025, 104: 144-151. PMID: 40329829, DOI: 10.5414/cn111677.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseaseDisease-causing variantsDominant polycystic kidney diseaseFamily historyPolycystic kidney diseaseAutosomal dominant polycystic kidney disease phenotypeKidney diseaseHistory of autosomal dominant polycystic kidney diseaseFamily history of autosomal dominant polycystic kidney diseaseSingle-center experienceApparent family historyThomas Jefferson University HospitalGenetic test resultsADPKD patientsPKD patientsKidney functionGenetic diagnosisGenetic testingUniversity HospitalAccurate diagnosisPatientsKidney failureClinical diagnosisDisease accountPracticing nephrologistsDietary Oxalate Nephropathy Due to Pureed Feeds
Panchal R, Rytting H, Chinnadurai A, Greenbaum L. Dietary Oxalate Nephropathy Due to Pureed Feeds. Kidney Medicine 2025, 7: 101048. PMID: 40740720, PMCID: PMC12304925, DOI: 10.1016/j.xkme.2025.101048.Peer-Reviewed Original ResearchOxalate nephropathyUrinary oxalateHigher intake of foodsSecondary oxalate nephropathyChronic high intakePureed foodsIntake of foodIntake of oxalateCounselling of childrenElevated creatinineKidney biopsyTubular injuryDietary modificationDietary intakeNutritional counselingPrimary hyperoxaluriaKidney functionOxalate intakeGenetic testingKidney failureDietary intake of oxalateKidney stonesKidneyCreatinineNephropathyAssociation of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure
Moises A, Tighiouart H, Testani J, Tuttle M, Banlengchit R, Oka T, Lee K, Ferguson K, Sarnak H, Harding C, Kiernan M, Sarnak M, McCallum W. Association of Volume Overload With Kidney Function Outcomes Among Patients With Acute Decompensated Heart Failure. American Journal Of Kidney Diseases 2025, 86: 324-334.e1. PMID: 40484339, PMCID: PMC12354306, DOI: 10.1053/j.ajkd.2025.03.026.Peer-Reviewed Original ResearchPulmonary capillary wedge pressureHigh central venous pressureCentral venous pressureAssociation of central venous pressureDecompensated heart failureRisk of dialysisVolume overloadInitiation of dialysisEGFR slopeHeart failureKidney functionDegree of volume overloadLow baseline kidney functionAcute decompensated heart failureRisk factorsAssociated with lower eGFRRight heart catheterizationCox proportional hazards regression modelsCapillary wedge pressureInitial central venous pressureAssociated with increased riskProportional hazards regression modelsBaseline kidney functionKidney function outcomesRestricted cubic splinesChanges in kidney functions following acute infusion of low molecular weight polyvinylpyrrolidone in male rats
Yan Q, Yan Q, Shen H, Wang T. Changes in kidney functions following acute infusion of low molecular weight polyvinylpyrrolidone in male rats. Physiological Reports 2025, 13: e70295. PMID: 40156095, PMCID: PMC11953058, DOI: 10.14814/phy2.70295.Peer-Reviewed Original ResearchConceptsBlood urea nitrogenNatriuretic effectRenal functionProximal tubular absorptionRenal clearance experimentsAlpha 1-microglobulinKaliuretic effectAcute administrationAcute infusionUrine volumeMale ratsProximal tubulesRenal damageKidney functionNephron segmentsUrinary concentrationsInfusionClearance experimentsUrea nitrogenTubular absorptionTissue preparationsExcretionWater-soluble homopolymersElectrolyte absorptionRatsChronic kidney disease
Romagnani P, Agarwal R, Chan J, Levin A, Kalyesubula R, Karam S, Nangaku M, Rodríguez-Iturbe B, Anders H. Chronic kidney disease. Nature Reviews Disease Primers 2025, 11: 8. PMID: 39885176, DOI: 10.1038/s41572-024-00589-9.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseKidney functionPresence of concomitant risk factorsRisk factorsSodium-glucose transporter 2Abnormalities of kidney functionConcomitant risk factorsManagement of patientsExcretory kidney functionKidney replacement therapyRenin-angiotensin systemModifiable risk factorsAssociated with accelerated cardiovascular diseaseSecondary hyperparathyroidismSequential injuryPersistent abnormalitiesReplacement therapySodium-glucoseCardiovascular morbidityMetabolic acidosisSevere infectionsCKD progressionKidney diseaseKidney failureTransporter 2Novel Hemodynamic Markers and Kidney Function in Patients with Acute Decompensated Heart Failure
Tuttle M, Banlengchit R, Tighiouart H, Testani J, Moises A, Oka T, Ferguson K, Sarnak H, Harding C, Kiernan M, Sarnak M, McCallum W. Novel Hemodynamic Markers and Kidney Function in Patients with Acute Decompensated Heart Failure. Kidney360 2025, 6: 728-738. PMID: 40440457, PMCID: PMC12136642, DOI: 10.34067/kid.0000000703.Peer-Reviewed Original ResearchPulmonary artery pulsatility indexAcute decompensated heart failureAortic pulsatility indexDecompensated heart failureBaseline eGFREGFR slopePulmonary arteryPulsatility indexHeart failureLower pulmonary artery pulsatility indexKidney functionPatients admitted with acute decompensated heart failureMedian follow-up timeMultivariate Cox proportional hazards modelHemodynamic markersArtery pulsatility indexRisk of dialysisFollow-up timeLeft ventricular functionFollow-up periodCox proportional hazards modelsAssociated with higher hazardsProportional hazards modelUnique patient admissionsQuaternary medical center
2024
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Noronha I, Trimarchi H, Hou F, Renfurm R, Gray T, Camargo M, Barratt J. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney International Reports 2024, 10: 217-226. PMID: 39810771, PMCID: PMC11725817, DOI: 10.1016/j.ekir.2024.10.004.Peer-Reviewed Original ResearchRenin-angiotensin system inhibitorsEndothelin-AStable doseIgA nephropathyEndothelin-A receptor antagonistSodium-glucose cotransporter-2 inhibitorsPlacebo-controlled clinical trialRenin-angiotensin system inhibitor therapyBiopsy-proven IgANBaseline to weekCotransporter-2 inhibitorsMethods Eligibility criteriaKidney function lossRandomized Controlled StudyDouble-blindReceptor antagonistReduce proteinuriaEGFR changeBaseline characteristicsSystem inhibitorsIgAN populationAtrasentanKidney functionKidney inflammationClinical trials9360 Evaluating The More Accurate Indicator Of Kidney Function In Mild Autonomous Cortisol Secretion: EGFR Creatinine Versus EGFR Cystatin
Rahimi L, Saini J, Atkinson E, Achenbach S, Kattah A, Bancos I. 9360 Evaluating The More Accurate Indicator Of Kidney Function In Mild Autonomous Cortisol Secretion: EGFR Creatinine Versus EGFR Cystatin. Journal Of The Endocrine Society 2024, 8: bvae163.178. PMCID: PMC11453792, DOI: 10.1210/jendso/bvae163.178.Peer-Reviewed Original ResearchDexamethasone suppression testAutonomous cortisol secretionAssessment of kidney functionIndicator of kidney functionSkeletal muscle atrophyKidney functionMAC cohortReference subjectsFat massLean massAssociated with higher fat massMuscle atrophyOvernight dexamethasone suppression testCortisol secretionTotal body fat massPrevalence of cardiovascular comorbiditiesTotal body lean massDegree of kidney dysfunctionHigher fat massBody fat massLow lean massBody lean massChronic kidney diseaseDistribution of BMIKruskal-Wallis testHigher prevalence of kidney function impairment among older people living with HIV in Uganda
Ssemasaazi A, Kalyesubula R, Manabe Y, Mbabazi P, Naikooba S, Ssekindi F, Nasuuna E, Byakika-Kibwika P, Castelnuovo B. Higher prevalence of kidney function impairment among older people living with HIV in Uganda. BMC Nephrology 2024, 25: 321. PMID: 39334034, PMCID: PMC11428404, DOI: 10.1186/s12882-024-03761-1.Peer-Reviewed Original ResearchConceptsKidney function impairmentChronic kidney diseaseAntiretroviral therapyOlder PLWHFunctional impairmentKidney functionKidney diseaseHIV-related inflammationProgression of kidney diseasePrevalence of proteinuriaMultivariate logistic regression modelBurden of chronic kidney diseaseMeasures of kidney functionDiagnosis of hypertensionCross-sectional studyConclusionsHIV infectionHIV-related clinical characteristicsClinical characteristicsInstitution of measuresLogistic regression modelsDiabetes mellitusFemale sexHIVProteinuriaPLWHMechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightA plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich H, Rovin B, Barratt J. A plain language summary of the NefIgArd trial: Nefecon for the treatment of patients with immunoglobulin A nephropathy. Future Rare Diseases 2024, 4: 2380247. DOI: 10.1080/23995270.2024.2380247.Peer-Reviewed Original ResearchClinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study
Xu L, Chen X, Yang X, Chen S, Yang M, Yuan Z, Chen R, Wang J, Jiang H, Xu J, Wang Y. Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. Frontiers In Cellular And Infection Microbiology 2024, 14: 1392491. PMID: 39211792, PMCID: PMC11358093, DOI: 10.3389/fcimb.2024.1392491.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsCOVID-19 pneumoniaViral shedding timeRetrospective cohort studyShort-term prognosisTransplant recipientsClinical featuresAntiviral drugsAntiviral medicationsCohort studyShort-term renal functionAdministration of antiviral drugsAssociated with better therapeutic outcomesSevere COVID-19 pneumoniaConcurrent coronavirus disease 2019Diagnosis of COVID-19 pneumoniaTransplanted kidney functionStatistically significant reductionShedding timeRenal functionSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Clinical symptomsKidney functionInitial symptomsIncidence of Acute Kidney Injury and Associated Mortality among Individuals with Drug-Susceptible Tuberculosis in Uganda
Kansiime G, Aklilu A, Baluku J, Yasmin F, Kanyesigye M, Muzoora C, Wilson F, Bajunirwe F, Brewster U, Kalyesubula R. Incidence of Acute Kidney Injury and Associated Mortality among Individuals with Drug-Susceptible Tuberculosis in Uganda. Kidney360 2024, 5: 1446-1454. PMID: 39141693, PMCID: PMC11556924, DOI: 10.34067/kid.0000000000000551.Peer-Reviewed Original ResearchIncidence of acute kidney injuryAcute kidney injuryDiagnosis periodKidney injuryKDIGO-defined acute kidney injuryKidney functionTB diagnosisPredictors of acute kidney injuryTime to TB diagnosisAssociated with significant risk of mortalityIndependent of HIV statusOverall incidence of AKIAssociated with increased mortality riskCohort study of adultsAssociated with higher oddsAssociated with significant mortalityDrug-susceptible TBDrug-susceptible tuberculosisObservational cohort study of adultsAssociated with significant riskHIV-negative participantsSignificant risk of mortalityObservational cohort studyStudy of adultsMonitoring kidney functionClinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study
Wang Z, Zhou X, Shi S, Liu L, Lv J, Zhang H. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study. American Journal Of Nephrology 2024, 55: 529-538. PMID: 39074466, DOI: 10.1159/000540268.Peer-Reviewed Original ResearchConceptsEnd-stage kidney diseaseC2 lesionsCohort studyCox regressionMonths prior to biopsyPeking University First HospitalProportion of crescentsMultivariate Cox regressionProspective cohort studyEffective treatment strategiesKidney prognosisImmunosuppressive treatmentRenal prognosisT2 lesionsMean proteinuriaCombined steroidCrescentic lesionsOxford classificationGlomerular crescentsClinical prognosisUnivariate analysisPathological findingsClinical significanceIgA nephropathyKidney functionProtein Intake and High Uric Acid Stone Risk
Montgomery T, Nair H, Phadke M, Morhardt E, Ludvigson A, Motamedinia P, Singh D, Dahl N. Protein Intake and High Uric Acid Stone Risk. Kidney Medicine 2024, 6: 100878. PMID: 39279882, PMCID: PMC11399574, DOI: 10.1016/j.xkme.2024.100878.Peer-Reviewed Original ResearchUric acid stone formersKidney stone formersUric acid stone formationStone formersChronic kidney diseaseStone analysisProtein intakeRetrospective studyKidney functionKidney diseaseAssociated with protein intakeUric acidStone formationLow urine citrateDietary protein intakeDiminished kidney functionProtein catabolic rateBody mass indexUrine urea nitrogenUric acid nephrolithiasisChi-square testPrevalence of uric acid nephrolithiasisUrine citrateNephrology clinicMass index
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply